



PRESS RELEASE

LAC Med inks underwriting agreement for Main Market IPO

- *Appoints RHB, Alliance as Joint Underwriters*
- *Listing to drive market expansion with diversified portfolio of brands and solutions, strengthen recurring income, support regional growth*

Selangor, Malaysia, 28 October 2025 - Leading medical devices and integrated solutions provider LAC Med Berhad (LAC Med or the Group) entered into an underwriting agreement with RHB Investment Bank Berhad (RHB) and Alliance Islamic Bank Berhad (Alliance) in conjunction with its planned initial public offering (IPO) on the Main Market of Bursa Malaysia Securities Berhad (Bursa Securities).

The proceeds raised from the IPO will enable LAC Med to accelerate market expansion and broaden the Group's portfolio of medical devices and solutions to meet growing demand. As an end-to-end solutions provider for supplying and integrating medical devices, the Group supports over 300 active clients across the healthcare sector and has an extensive installed base of more than 2,500 units of medical equipment in Malaysia.

To strengthen its recurring income streams after the listing, LAC Med will expand into two new business segments, Equipment-as-a-Service (EaaS) and Medical Device Asset Management Services (MEAMS). EaaS offers customised solutions comprising equipment bundled with managed software platform under a subscription-based model which meets the specific needs of healthcare providers. MEAMS is a software solution designed for equipment tracking to optimise asset utilisation and reduce downtime.

Furthermore, a portion of the IPO proceeds raised will be allocated to support regional expansion into Indonesia to capture growing opportunities in the country's healthcare market. In addition, the Group intends to relocate to a new head office with expanded storage facility, as well as establishment of a showroom dedicated for product demonstration.

Apart from the above, the balance proceeds will be utilised for repayment of borrowings, working capital, and defrayment of listing expenses.

"We are committed to delivering advanced, integrated medical solutions that enhance patient care and strengthen operational efficiency for healthcare providers. Our IPO will drive the expansion of our solutions and services, and our collaboration with leading international brands will ensure we provide the market with superior and comprehensive offerings.

Moreover, we are enhancing our recurring income streams via our high-growth, subscription-based medical platforms, while simultaneously funding our strategic entry into the Indonesian market.

We strongly believe that being listed on Bursa Securities will position us with heightened credibility among clients and suppliers, positioning us for long-term success as we pursue sustainable growth over the next decades."

Mr. Liew Yoon Poh ("刘任堡")

Group Chief Executive Officer of LAC Med Berhad

LAC MED BERHAD 202401049485 (1595329H)

G-03A-3, Plaza Kelana Jaya, Jalan SS7/13A, 47301 Petaling Jaya, Selangor, Malaysia.

Tel: 03-7652 1088

Ref. No.: LACMED/SC/2505-01



“We are honoured to act as the Principal Adviser, Sole Placement Agent, and Joint Underwriter for the IPO of LAC Med Berhad, a leading medical devices solutions provider. This milestone represents a pivotal advancement in the Group’s mission to deliver innovative medical solutions that enhance standards of care and improve patient outcomes in the healthcare sector.

This IPO demonstrates the depth and resilience of Malaysia’s capital market in enabling homegrown companies with scalable, impactful solutions to access the capital they need to grow and expand locally and regionally.

RHB Investment Bank Berhad is proud to champion the Group in its IPO journey and we look forward to supporting the Group in its next phase of expansion.”

Mr. Kevin Davies

Chief Executive Officer of RHB Investment Bank Berhad

“Alliance Islamic Bank Berhad is pleased to collaborate as a Joint Underwriter in supporting LAC Med Berhad’s journey towards becoming a public listed company. The Group’s established track record in providing integrated medical device solutions and its experienced management team form a solid foundation for sustainable expansion.

From an investor’s perspective, this IPO provides access to Malaysia’s fast-growing medical supplies market through an entity with a proven track record and potential. This collaboration reflects our continued commitment to supporting the development of dynamic Malaysian enterprises in the healthcare and medical technology industry.”

En. Rizal IL-Ehzan Bin Fadil Azim

Chief Executive Officer of Alliance Islamic Bank Berhad

The IPO is targeted for listing on the Main Market of Bursa Securities in December 2025.

LAC Med offers comprehensive end-to-end services from initial preliminary planning and facility design, custom interior fit-outs, equipment procurement and installation, system integration, testing and commissioning, to post-installation support services including training, technical support and maintenance services.

The Group represents leading international medical brands, including Samsung and Philips, with which LAC Med holds long-standing relationships since 2013 and 2017 respectively. Since 2023, the Group has also become the authorised distributor for Stryker, LG, Epson, SwiftMR, Abbott, annalise.ai, Alpinion, Baxter and Bayer, significantly strengthening its product portfolio and its ability to deliver complete solutions for clients.

For the IPO exercise, RHB is the Principal Adviser, Joint Underwriter and Sole Placement Agent, while Alliance is the Joint Underwriter.

LAC MED BERHAD 202401049485 (1595329H)

G-03A-3, Plaza Kelana Jaya, Jalan SS7/13A, 47301 Petaling Jaya, Selangor, Malaysia.

Tel: 03-7652 1088

Ref. No.: LACMED/SC/2505-01

About LAC Med Berhad (LAC Med; the Group)



The Group is a leading medical devices and integrated solutions provider. Since 2003, LAC Med via its subsidiaries, has established itself as a trusted partner to service providers in the healthcare sector. LAC Med has installed an extensive base of more than 2,500 units of medical equipment and supports over 300 active clients across Malaysia's healthcare sector, including private and public healthcare institutions, university hospitals, local health offices, medical device suppliers and concessionaire companies.

LAC Med's competencies extend from initial preliminary planning and facility design, custom interior fit-outs, equipment procurement and installation, system integration, testing and commissioning, to post-installation support services including training, technical support and maintenance services.

As an authorised distributor in Malaysia, LAC Med supplies and installs third-party brands of medical devices comprising medical equipment and associated products, which include medical consumables and provision of software and system integration.

LAC Med represents leading international medical brands including Samsung and Philips, with which it holds long-standing relationships since 2013 and 2017 respectively. Since 2023, the Group has also become the authorised distributor for Stryker, LG, Epson, SwiftMR, Abbott, annalise.ai, Alpinion, Baxter and Bayer, significantly strengthening its portfolio and its ability to deliver complete solutions for clients.

**Issued for and on behalf of LAC MED BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd.
For media and investor relations enquiries, please contact:**

Mr. Terence Loo terence@aquilas.com.my

T:03-2711 1391/ M: 012-629 5618

Mr. Tee Wei Keat weikeat@aquilas.com.my

T:03-2711 1391/ M: 012-309 5448